About Ibio (NYSEAMERICAN:IBIO)
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.
Industry, Sector and Symbol
SectorPharmaceuticals - NEC
Trailing P/E Ratio-1.05882352941176
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on Equity-205.31%
Return on Assets-44.21%
Ibio (NYSEAMERICAN:IBIO) Frequently Asked Questions
What is Ibio's stock symbol?
Ibio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."
Are investors shorting Ibio?
Ibio saw a increase in short interest during the month of December. As of December 29th, there was short interest totalling 612,033 shares, an increase of 64.2% from the December 15th total of 372,651 shares. Based on an average daily trading volume, of 1,033,877 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.8% of the shares of the stock are short sold.
Who are some of Ibio's key competitors?
Some companies that are related to Ibio include Evoke Pharma (EVOK), Apricus Biosciences (APRI), AzurRx BioPharma (AZRX), Concordia International (CXRX), IntelliPharmaCeutics Intl (IPCI), Neuralstem (CUR), Pernix Therapeutics (PTX), Eyegate Pharmaceuticals (EYEG), Cellectar Biosciences (CLRB), N4 Pharma (N4P), Venture Life Group (VLG), Immune Pharmaceuticals (IMNP), SLS International (SLS), Avanir Pharmaceuticals (AVNR), Cadence Pharmaceuticals (CADX), Forest Laboratories (FRX), Hi-Tech Pharmacal (HITK) and Questcor Pharmaceuticals (QCOR).
Who are Ibio's key executives?
Ibio's management team includes the folowing people:
- Robert B. Kay, Executive Chairman of the Board, Chief Executive Officer (Age 76)
- Robert L. Erwin, President (Age 63)
- James P. Mullaney, Chief Financial Officer (Age 46)
- Terence Ryan Ph.D., Chief Scientific Officer (Age 61)
- Glenn J. Chang CPA, Independent Director (Age 68)
- Arthur Y. Elliott Ph.D., Independent Director (Age 80)
- Seymour Flug, Independent Director (Age 81)
- James T. Hill, Independent Director (Age 70)
- John D. McKey Jr., Independent Director (Age 73)
How do I buy Ibio stock?
Shares of Ibio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ibio's stock price today?
One share of Ibio stock can currently be purchased for approximately $0.18.
How big of a company is Ibio?
Ibio has a market capitalization of $20.77 million.
How can I contact Ibio?
Ibio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650.
MarketBeat Community Rating for Ibio (IBIO)MarketBeat's community ratings are surveys of what our community members think about Ibio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ibio (NYSEAMERICAN:IBIO) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Ibio (NYSEAMERICAN:IBIO) Earnings History and Estimates Chart
Ibio (NYSEAMERICAN IBIO) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Ibio (NYSEAMERICAN:IBIO) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Ibio (NYSEAMERICAN:IBIO)
No dividend announcements for this company have been tracked by MarketBeat.com
Ibio (NYSEAMERICAN IBIO) Insider Trading and Institutional Ownership History
Ibio (NYSEAMERICAN IBIO) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/30/2017||Eastern Capital Ltd||Major Shareholder||Buy||12,000,000||$0.20||$2,400,000.00||45,744,000|| |
|4/7/2016||Eastern Capital Ltd||Major Shareholder||Buy||6,500,000||$0.62||$4,030,000.00||33,744,000|| |
|1/25/2016||Eastern Capital Ltd||major shareholder||Buy||3,500,000||$0.62||$2,170,000.00||27,244,000|| |
|9/17/2014||Carl Desantis||Major Shareholder||Sell||138,710||$0.67||$92,935.70|| |
|2/3/2014||Carl Desantis||Major Shareholder||Sell||28,828||$0.55||$15,855.40|| |
|1/31/2014||Carl Desantis||Major Shareholder||Sell||74,049||$0.56||$41,467.44|| |
|1/29/2014||Carl Desantis||Major Shareholder||Sell||128,708||$0.58||$74,650.64|| |
|8/13/2013||Carl Desantis||Major Shareholder||Sell||37,689||$0.50||$18,844.50|| |
|8/8/2013||Carl Desantis||Major Shareholder||Sell||324,395||$0.54||$175,173.30|| |
|8/6/2013||Carl Desantis||Major Shareholder||Sell||53,065||$0.50||$26,532.50|| |
|8/2/2013||Carl Desantis||Major Shareholder||Sell||99,945||$0.50||$49,972.50|| |
|7/30/2013||Carl Desantis||Major Shareholder||Sell||34,605||$0.51||$17,648.55|| |
|7/26/2013||Carl Desantis||Major Shareholder||Sell||27,255||$0.50||$13,627.50|| |
|7/23/2013||Carl Desantis||Major Shareholder||Sell||39,465||$0.51||$20,127.15|| |
|7/19/2013||Carl Desantis||Major Shareholder||Buy||1,732,679||$0.52||$900,993.08|| |
Ibio (NYSEAMERICAN IBIO) News Headlines
|Short Interest in Ibio Inc (IBIO) Increases By 64.2%|
www.americanbankingnews.com - January 10 at 5:38 PM
|iBio, Inc. Provides Corporate Update - GlobeNewswire (press release)|
globenewswire.com - January 6 at 3:31 PM
|iBio, Inc. Provides Corporate Update|
www.nasdaq.com - January 6 at 9:10 AM
|Ibio Inc (IBIO) Short Interest Up 15.3% in December|
www.americanbankingnews.com - December 27 at 7:24 PM
|ETFs with exposure to iBio, Inc. : December 18, 2017|
finance.yahoo.com - December 19 at 10:24 AM
|ETFs with exposure to iBio, Inc. : December 8, 2017|
finance.yahoo.com - December 8 at 3:30 PM
|iBio Inc (IBIO): Does -31.1% EPS Decline Lately Make It An Underperformer?|
finance.yahoo.com - December 8 at 3:30 PM
|Ibio Inc (IBIO) Major Shareholder Buys $2,400,000.00 in Stock|
www.americanbankingnews.com - December 4 at 5:48 PM
|iBio, Inc. Closes $4,500,000 Offering of Common Stock|
finance.yahoo.com - December 1 at 2:58 PM
|iBio, Inc. (IBIO) Plans Public Offering of Common Stock|
www.streetinsider.com - November 29 at 3:30 PM
|Mid-Day ETF Update: ETFs, Stocks Mixed as Street Digests Q3 GDP Data, Yellen Remarks|
www.nasdaq.com - November 29 at 3:30 PM
|Wall Street Sees Narrowly Mixed Open as Traders Digest Q3 GDP, Yellen Remarks|
www.nasdaq.com - November 29 at 10:29 AM
|Pre-Open Movers 11/29: (PETX) (NUAN) (MLNT) Higher; (WAIR) (ADSK) (TDOC) Lower (more...)|
www.streetinsider.com - November 29 at 10:29 AM
|BRIEF-Ibio Inc Prices $4.50 Mln Firm Commitment Offering Of Common Stock|
www.reuters.com - November 29 at 10:29 AM
|iBio, Inc. Prices $4,500,000 Firm Commitment Offering of Common Stock|
finance.yahoo.com - November 29 at 10:28 AM
|Ibio Inc (IBIO) Sees Significant Growth in Short Interest|
www.americanbankingnews.com - November 27 at 8:24 PM
|ETFs with exposure to iBio, Inc. : November 27, 2017|
finance.yahoo.com - November 27 at 5:27 PM
|ETFs with exposure to iBio, Inc. : November 14, 2017|
finance.yahoo.com - November 14 at 8:15 PM
|Ibio Inc (IBIO) Short Interest Down 78.6% in October|
www.americanbankingnews.com - November 14 at 12:02 AM
|iBio, Inc. :IBIO-US: Earnings Analysis: Q1, 2018 By the Numbers : November 13, 2017|
finance.yahoo.com - November 13 at 7:45 PM
Ibio (NYSEAMERICAN:IBIO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Ibio (NYSEAMERICAN:IBIO) Income Statement, Balance Sheet and Cash Flow Statement
Ibio (NYSEAMERICAN IBIO) Stock Chart for Sunday, January, 21, 2018